HC Wainwright Adjusts Earnings Estimate for Corcept Therapeutics in FY2026

Corcept Therapeutics Incorporated (NASDAQ:CORT) has recently seen an upgrade in its earnings estimates for the fiscal year 2026, as reported by HC Wainwright. In a research note published on Thursday, October 31st, analyst S. Ramakanth raised the earnings per share (EPS) forecast for the biotechnology firm from $3.55 to $3.67. This positive adjustment reflects the firm's optimistic outlook on Corcept's financial performance.

Analyst Ratings and Price Target

HC Wainwright has reiterated its "Buy" rating on Corcept Therapeutics, alongside a price target of $80.00 per share. This comes as part of a broader trend, as the current consensus estimate points to expected earnings of $1.12 per share for the entire fiscal year.

Expanding its forecast beyond FY2026, HC Wainwright also projected earnings of $4.78 per share for FY2027 and $5.64 per share for FY2028. This indicates a bullish sentiment about the company's growth potential and market prospects.

Recent Analyst Activity

Other analysts have also expressed positive sentiments regarding Corcept Therapeutics. For instance, Sandler O’Neill confirmed a "buy" rating on the company's shares. Truist Financial adjusted their price target from $65.00 to $76.00 while maintaining a "buy" rating as well. StockNews.com enhanced their outlook on Corcept by upgrading it from a "buy" to a "strong-buy" rating.

Canaccord Genuity Group kept a "buy" rating with a $38.00 price target, while Piper Sandler increased their price target from $38.00 to $67.00. The overall consensus from five investment analysts currently rates the stock as a buy, with an average price target of approximately $65.25.

Corcept Therapeutics Stock Performance

As of Friday, shares of Corcept Therapeutics opened at $47.62. The company has a market capitalization of $4.98 billion and a P/E ratio of 37.79. Over the past 52 weeks, the stock has fluctuated, reaching a low of $20.84 and a high of $50.07. Additionally, the stock has maintained a 50-day simple moving average of $42.40 and a 200-day simple moving average of $34.57.

Quarterly Earnings Results

On October 30th, Corcept Therapeutics reported its quarterly earnings, revealing earnings of $0.41 per share, which exceeded the analysts' expectations of $0.27. Revenues for the quarter reached $182.55 million, surpassing the consensus estimate of $171.97 million and representing a year-over-year revenue increase of 47.7%.

Institutional and Insider Trading

Recently, significant institutional investments have been noted, with firms such as Capital Performance Advisors and Park Place Capital Corp acquiring shares. Hedge funds and institutional investors hold a substantial portion of the company, owning about 93.61% of its stock.

Insider trading activity has also been recorded, with Gary Charles Robb, an insider, selling 11,000 shares at an average price of $46.28. Following this transaction, he retains 22,772 shares valued at over $1 million. Another insider, William Guyer, sold 10,000 shares at $35.30 each, reflecting a slight decrease in their holdings.

About Corcept Therapeutics

Corcept Therapeutics specializes in the discovery and development of medications aimed at treating serious disorders in various fields, including endocrinology and oncology. One of its notable products is Korlym, which is prescribed for managing hyperglycemia related to conditions such as Cushing's syndrome.

earnings, estimate, stocks